Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As It Prepares for a Future with Wyeth, Pfizer Reports Ho-Hum Q1 Results

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer’s first-quarter results were down, but in line with the company’s and Wall Street’s expectations.

You may also be interested in...



Pfizer’s Business Units Enable It To Be Nimble Even as It Grows

Wyeth integration is on track, with closing expected end of Q3 or Q4; anti-trust review is in early stages, with concern primarily about animal health overlap.

HBV Approval Gives Viread A Needed Boost

U.S. clearance follows nod from European regulators.

HBV Approval Gives Viread A Needed Boost

U.S. clearance follows nod from European regulators.

Related Content

Topics

UsernamePublicRestriction

Register

PS069346

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel